Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

NCT01802632 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01802632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01802632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
March 4, 2013
Completion date
December 11, 2023
Enrollment
603 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

advanced (inoperable) non small cell lung cancer, advanced non small cell lung cancer